Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...
A nearly 30-year study shows a strong long-term association between very high lipoprotein(a) levels and cardiovascular ...
Icosapent ethyl (Vascepa; Amarin) remains effective at reducing cardiovascular events in patients with elevated triglycerides but relatively well-controlled LDL cholesterol on a statin irrespective of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback